Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Immunology
Zemi Dossier
Research-use only
Fibrosis as Failed Resolution
A decision package on treating fibrosis as a stalled resolution system rather than a generic scar-reduction problem.
Decision this dossier helps answer
Which fibrosis programs target the binding resolution node, and what would show whether repair can occur without destabilizing tissue integrity?
Problem this dossier solves
The scar is the record; failed resolution is the active system.
The dossier shifts the buyer lens from reducing fibrosis to restoring resolution. It maps when myofibroblast persistence, matrix lock-in, immune state, or repair risk is the true bottleneck, and which study would change the decision.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
116-page research report plus 41-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The scar is the record; failed resolution is the active system.
The dossier shifts the buyer lens from reducing fibrosis to restoring resolution. It maps when myofibroblast persistence, matrix lock-in, immune state, or repair risk is the true bottleneck, and which study would change the decision.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Fibrosis as Failed Resolution research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Decision Brief | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Contents | Shows the report structure and where to inspect the argument, evidence, workbook logic, and limits. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Matrix | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Buy Build Wait Avoid | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Dashboard | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The Resolution Restoration Index | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Why the index is a product, and what that buys analytically | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Resolution Restoration Classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Current Signal Update 2025 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current-signal refresh (verified 13 June 2026) | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Organ Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The kidney completes the cross-organ picture: metabolic and EndMT convergence | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Domain Synthesis | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidence Maturity and Platform Matrix | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Comparative Platform Mechanism Matrix | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Competitive Landscape | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Connects research claims to practical diligence and monitoring decisions. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The thesis | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Two-population law | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Node 1: reversion | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Node 2: clearance | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Node 3: efferocytosis | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Node 4: matrix | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Node 5: metabolic/reserve | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross-organ transfer | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cardiac white space | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Reversal biomarker | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Endpoint trap | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Anti-fibrogenic backbone | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Liver: reversal signals | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Single-node failures | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| AI-discovered targets | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1. Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Point-in-time, June 2026 . evidence window to. fields and clipped entries such as Source-audit reconciliation, 134 audited = 89. |
| 2 | 2. Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, claim_text, report_section, report_page fields and clipped entries such as CF-001, Nerandomilast (BI 1015550), a., Clinical &. |
| 3 | 3. Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes NCT:NCT04069312, Roflumilast or Azithromycin to., ClinicalTrials.gov, 2020-02-11 fields and clipped entries such as NCT:NCT06003426, A. |
| 4 | 4. Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes claim_id, primary_source_id, customer_facing_claim, source_support_verdict fields and clipped entries such as CF-001, PMID:40388329, Nerandomilast (BI. |
| 5 | 5. Source-Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Source-support verdicts, 60 exact / 51 partial / 0 other, Separated from the all-claim. fields and clipped entries such as Source-pack audit, 134. |
| 6 | 6. RRI-Node Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes RRI node, Evidence count, Role in reversal, Maturity fields and clipped entries such as Reversion, turn the myofibroblast OFF, preclinical (1 human. |
| 7 | 7. Organ-Strategy Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Heart (post-MI/HFpEF/AS), HIGHEST-VALUE TRANSFER white space, YES - CMR-ECV (non-invasive,., NO fields and clipped entries such as Liver. |
| 8 | 8. Asset & Company Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Agent / sponsor, Mechanism, Stage / channel, Reverses? fields and clipped entries such as Nerandomilast / Boehringer Ingelheim, PDE4B inhibitor,. |
| 9 | 9. Trial-Catalyst Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, Title, Phase, Status fields and clipped entries such as NCT01371305, Randomized, Double-Blind,., PHASE2. |
| 10 | 10. Senescence & Resolution | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Finding, Role, Mechanism, Implication fields and clipped entries such as BCL-2 apoptosis-resistance, persistence lock 1,. |
| 11 | 11. Reversal-Biomarker Tracker | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes Biomarker, Measures, Organ, Status fields and clipped entries such as Collagen triple-helix denaturation., active collagen remodeling,. |
| 12 | 12. Mechanotransduction-Matrix | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Mechanism, Effect, Intervention, Maturity fields and clipped entries such as Piezo1 stiffness-Ca2+, re-activates fibroblasts,. |
| 13 | 13. Cross-Organ Transfer Matrix | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Mechanism, Lung, Liver, Heart fields and clipped entries such as CTHRC1+ activated myofibroblast, +++, ++. |
| 14 | 14. Regulatory-Endpoint Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Item, Status / channel (named), Note, Source fields and clipped entries such as Fibrosis approval endpoint, FVC slope / progression. |
| 15 | 15. Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes figure_id (Fig #), figure_id, figure_family, section_anchor fields and clipped entries such as Fig 1, fig27_opportunity_gap,. |
| 16 | 16. Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes Fig #, Figure ID, Backend, Data type fields and clipped entries such as fig27_opportunity_gap, deterministic, expert-ordinal. |
| 17 | 17. Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes H#, Tier, Class, Title (novelty-vs-obvious) fields and clipped entries such as H1, Frontier - RRC validation cohort, Mechanistic. |
| 18 | 18. MV Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes study_id, study_name, population, intervention fields and clipped entries such as MVNS-1, Resolution-module proof-of-mechanism., Donor IPF. |
| 19 | 19. Verification-Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Source/DB, Query / action, Result, Note fields and clipped entries such as VERIFY, PubMed/NCBI esummary+efetch (PMIDs), 117/117. |
| 20 | 20. Excluded Claims (45) | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Claim label, Bucket, Citations, Reason fields and clipped entries such as Excluded 6 — ABSI z-score threshold., off-topic (below. |
| 21 | 21. Quarantined Sources | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Item, Source, Reason, Disposition fields and clipped entries such as Thrombospondin dense-particle wound.,. |
| 22 | 22. Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Recovered / added item, Type, How grounded, Source fields and clipped entries such as Resolvin D2 (RvD2)., recovered from. |
| 23 | Evidence Maturity Matrix Data | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes Mechanism / RRI node, Mechanistic strength, Preclinical (animal), Human observational fields and clipped entries such as Reversion (KLF4:SOX4. |
| 24 | Safety - Risk Tracker | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Safety signal / failure mode, Mechanism, Node / organ, Severity (analyst) fields and clipped entries such as Ventricular rupture / scar dehiscence,. |
| 25 | Manufacturing - CMC - Operation | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Modality, Scalability, Release / potency assay, Sterilization,. fields and clipped entries such as mRNA-LNP (hepatocyte-selective),. |
| 26 | Validation - Falsification Gate | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Gate, What CONFIRMS the thesis, What FALSIFIES it, Linked H / claim / study fields and clipped entries such as G1 Clearance is rate-limiting,. |
| 27 | 23. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as CF-001, Clinical & Translational Implications,. |
| 28 | 24. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Cross-organ transfer (+ / ++ /., +, ++, +++, + = sparse/single-source; ++ =. fields and clipped entries such as RRI-node maturity, preclinical /. |
| 29 | 25. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as H1, STUDY-1, Responders >=10% fibrotic-burden.. |
| 30 | 26. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality, RRI node fields and clipped entries such as GSK / Engitix, ECM-target discovery collaboration.,. |
| 31 | 27. Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Version, Date, Change, Owner fields and clipped entries such as v1.0, 2026-06-12, Initial release build. |
| 32 | 28. Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Release check, Severity, Resolution, Artifact fields and clipped entries such as Citation/claim traceability, Critical, All 111. |
| 33 | RRC_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Evidence completeness (0-1), fraction of the 5 readouts., ____ fields and clipped entries such as Scar status, active / established / mixed (is.,. |
| 34 | RRC_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Node (output class), Meaning (rubric: 3 = severe., Deficit 0-3 (ENTER), Weight (expert-init) fields and clipped entries such as REVERSION-LIMITED,. |
| 35 | RRC_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype (deficit scores), Dominant node, 2nd node (label), Confidence fields and clipped entries such as Clearance-limited IPF (default).,. |
| 36 | RRC_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Class (binding node), Recommended strategy, Primary functional endpoint, Required safety readout fields and clipped entries such as. |
| 37 | RRC_Organ_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Organ (entered form), Organ-matched transfer strategy, Contraindication., Safety flag fields and clipped entries such as lung, Reversion biology. |
| 38 | RRC_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Assay / readout, Node, Tier fields and clipped entries such as Single-cell/spatial CTHRC1+/ACTA2+ +., Reversion, Required. |
| 39 | RRC_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Archetype, Profile (deficits), Binding node, Matched move fields and clipped entries such as Clearance-limited IPF (default), clearance 3,. |
| 40 | RRC_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Validation cohort, RRC-classified fibrosis cohorts. fields and clipped entries such as Held-out AUC target, >= 0.80 (binding-node call predicts.,. |
| 41 | RRC_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes RRC element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Reversion node, KLF4:SOX4 reversion dial;. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| H1 | Responders >=10% fibrotic-burden reduction (collagen-turnover imaging... | Two-proportion | 0.3 | 0.05 | 0.80 | 36 | 43 |
| H2 | Senescent-myofibroblast (p16+/aSMA+) burden, combo vs best-mono | Two-proportion | 0.35 | 0.05 | 0.80 | 53 | 63 |
| H3 | Reversion-signature reduction (KLF4 up/SOX4 down) vs control under TGF-b | Two-sample t | 0.9 | 0.05 | 0.80 | 20 | 23 |
| H4 | Activation/collagen change, transient stiffness reset + backbone vs b... | Two-sample t | 0.8 | 0.05 | 0.80 | 25 | 30 |
| H5 | Cross-organ fibrogenic-marker reduction (>=3/4 organs) vs vehicle | Two-sample t | 0.8 | 0.05 | 0.80 | 25 | 30 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 116-page report + 41-sheet workbook
Buy now
- Decision research report (116 pages, PDF)
- Evidence & Decision Workbook (41 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price